Pharma Focus Asia

CG Oncology Unveiled Novel Cretostimogene Grenadenorepvec for Non-Muscle Invasive Bladder Cancer

CG Oncology has introduced a new treatment cretostimogene grenadenorepvec for high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) cases, particularly those with carcinoma in situ, with or without Ta or T1 (papillary) tumours.

This novel therapy is an investigational oncolytic immunotherapy delivered intravesically and is currently undergoing assessment in a phase 3 clinical trial named BOND-003. It targets patients with NMIBC who have not responded well to BCG treatment.

Additionally, cretostimogene grenadenorepvec is concurrently being assessed in a phase 2 trial (CORE-001) alongside pembrolizumab for the same condition. Furthermore, an investigator-sponsored trial is aimed to assess its effectiveness when paired with nivolumab specifically for the treatment of muscle invasive bladder cancer.

The therapy is actively undergoing clinical trials for bladder cancer treatment. Preliminary findings from the BOND-003 phase 3 trial showed promising results, with a 75.7 percent complete response rate at any point among patients receiving cretostimogene grenadenorepvec. Moreover, it demonstrated good tolerance, with no severe treatment-related adverse events observed.

Bladder cancer affects a substantial number of individuals, with estimates of over 82,000 new diagnoses in 2023. Non-muscle invasive bladder cancer (NMIBC) constitutes about 75 percent of these cases and is the most common type. It's the sixth most prevalent cancer in the US, with men accounting for three-quarters of newly diagnosed cases.

Cretostimogene Grenadenorepvec has gained both FDA fast track and breakthrough therapy designations for its potential in treating high-risk BCG-unresponsive non-muscle invasive bladder cancer.

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024